In high-sensitivity troponin assays, the specificity of the antibodies utilized is of utmost importance. As the clinically relevant concentration of cardiac troponin T is just nanograms per litre, even a minor cross-reactivity of the assay to skeletal troponin T isoforms could result in false positives.
During the last fiscal year HyTest’s consolidated revenue was 24.1 million euros, which equated to a year-on-year growth of 1.3%. This rate was low due to the exceptionally strong growth experienced in 2016.
An integral part of research is made up of the articles that are published in peer-reviewed journals. This year, three different studies conducted by our R&D team have already been published...
29.03.2018 Happy Easter!
We will be closed during the Easter weekend and will be back in the office again on Tuesday.
NT-proBNP is an established diagnostic and prognostic marker of heart failure (HF), which is a complex clinical syndrome and health problem that is associated with high morbidity and mortality rates.
28.03.2018 HyTest History Animation
HyTest was established in March 1994 and since our very first day we have worked hard on a daily basis to discover the very best solutions for the needs of our customers.
23.03.2018 Secure Your -10% Discount Now
Save money by ordering antibodies online. You can make your order using the discount code any time between now and 31st of May 2018.
We will participate the 15th China Association of Clinical Laboratory Practice Expo held at Chongqing International Expo Center, on 17-19 March.
31.01.2018 New! Human Recombinant SAA1 and SAA2
Serum amyloid A (SAA) is often used as a non-specific marker of inflammation. Its concentration in blood increases in response to inflammatory stimulus such as tissue injury, infection or trauma.
Heart failure is a severe health problem that is characterized by an increasing prevalence and economic cost.
10.01.2018 Come to Meet us at VMX Orlando
We will be present at the VMX: Veterinary Meeting & Expo
21.12.2017 Season's Greetings 2017
We appreciate working with you and hope that the holidays and the coming year will bring you happiness and success.
Canine parvovirus type 2 (CPV-2) causes a severe and highly contagious disease in dogs.
27.11.2017 IFCC Distinguished Award Ceremony
During the year 2017 in collaboration with IFCC and EFLM through the sponsorships of their awards, we have had an excellent opportunity to show our appreciation towards scientific work in the field of cardiovascular diseases.
On October 10th 2017, more than 100 visitors came together to celebrate the 5th anniversary of HyTest’s Chinese subsidiary.
30.10.2017 Supporting Assistance Dogs
In Finland, there are currently only 65 assistance dogs in operation. However, more are needed as the waiting time for a fully trained dog is currently several years.
30.10.2017 Meet us at Medica Exhibition in November
If you or your colleagues will attend the MEDICA 2017 - the World's Leading Medical Forum - from November 13 to 16, in Düsseldorf, Germany, please schedule a meeting with us.
27.09.2017 New Anti-BNP Antibodies
We have developed three new monoclonal antibodies specific to BNP.
27.09.2017 Sponsoring SensUs 2017 - Contest Winners
SensUs is an international biosensor competition where multidisciplinary teams of students compete on developing molecular biosensors for healthcare applications.
During the first half of the year, HyTest’s consolidated revenue grew to 13.1 million euros. The year-on-year revenue growth was 5%.